VEST Venous Graft External Support Pivotal Study

Last updated: February 3, 2025
Sponsor: Vascular Graft Solutions Ltd.
Overall Status: Completed

Phase

N/A

Condition

Cardiac Disease

Heart Disease

Coronary Artery Disease

Treatment

Coronary artery bypass vein grafts

VEST

Clinical Study ID

NCT03209609
CD0131
  • Ages > 21
  • All Genders

Study Summary

Prospective, multi-center, randomized, within-subject-controlled , trial, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo SVG CABG with arterial grafting of IMA to LAD and two or more saphenous vein grafts. In each patient, one SVG bypass will be randomized to be supported by the VEST, while another will not be supported and serve as control. Thus, the full cohort will provide a basis for comparison between two sets of SVGs: A VEST supported set; and an unsupported set.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Signed informed consent, inclusive of release of medical information, and HealthInsurance Portability and Accountability Act (HIPAA) documentation.

  2. Age 21 years or older.

  3. Planned and scheduled on-pump CABG.

  4. Two or more vein grafts to native vessels having at least 75% stenosis andcomparable runoff.

  5. IMA graft indicated for the LAD. Additional arterial grafts may be considered basedon practice guidelines.

  6. Appropriately sized and accessible target coronary arteries, with a minimum diameterof 1.5 mm and adequate vascular bed (without significant distal stenosis), asassessed by pre-operative cardiac angiography and verified by diameter gaugingintraoperatively.

Exclusion

Exclusion Criteria:

  1. Concomitant non-CABG cardiac surgical procedure.

  2. Prior cardiac surgery.

  3. Emergency CABG surgery.

  4. Contraindication for on-pump CABG with cardioplegic arrest (e.g. severely calcifiedaorta).

  5. Calcification at the intended anastomotic sites, as assessed upon opening of thechest and before randomization.

  6. Severe vein varicosity as assessed after vein harvesting and before randomization.

  7. History of clinical stroke within 3 months prior to randomization.

  8. Severe renal dysfunction (Cr>2.0 mg/dL).

  9. Documented or suspected untreated diffuse peripheral vascular disease such as:carotid stenosis or claudication of the extremities.

  10. Concomitant life-threatening disease likely to limit life expectancy to less thantwo years.

  11. Inability to tolerate or comply with required guideline-based post-operative drugregimen (antiplatelet plus statin) and/or inability to take aspirin.

  12. Inability to comply with required follow-ups including angiographic imaging methods (e.g. contrast allergy).

  13. Concurrent participation in an interventional (drug or device) trial.

Study Design

Total Participants: 224
Treatment Group(s): 2
Primary Treatment: Coronary artery bypass vein grafts
Phase:
Study Start date:
January 09, 2018
Estimated Completion Date:
September 25, 2024

Study Description

Clinical significance:

Coronary artery bypass grafting (CABG) remains the gold standard treatment for patients with multi-vessel coronary artery disease. Despite the proposed benefits of multiple arterial grafts, autologous saphenous vein grafts (SVGs) are still the most frequently used bypass conduits in CABG. Progressive SVG failure after CABG remains a key limitation to the long-term success of surgery.

Objective:

Coronary artery bypass grafting (CABG) remains the gold standard treatment for patients with multi-vessel coronary artery disease. Despite the proposed benefits of multiple arterial grafts, autologous saphenous vein grafts (SVGs) are still the most frequently used bypass conduits in CABG. Progressive SVG failure after CABG remains a key limitation to the long-term success of surgery.

Study design:

Prospective, multi-center, randomized, within-subject-controlled , trial, enrolling patients with multi vessel atherosclerotic coronary artery disease, scheduled to undergo SVG CABG with arterial grafting of IMA to LAD and two or more saphenous vein grafts. In each patient, one SVG bypass will be randomized to be supported by the VEST, while another will not be supported and serve as control. Thus, the full cohort will provide a basis for comparison between two sets of SVGs: A VEST supported set; and an unsupported set.

Connect with a study center

  • London Health Sciences Centre, University Hospital

    London, Ontario N6A 5A5
    Canada

    Site Not Available

  • Institut de Cardiologie de Montréal

    Montréal, Quebec H1T 1C8
    Canada

    Site Not Available

  • Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval

    Québec City, Quebec G1V 4G5
    Canada

    Site Not Available

  • University of Southern California

    Los Angeles, California 90033
    United States

    Site Not Available

  • Lutheran Hospital of Indiana

    Fort Wayne, Indiana 46804
    United States

    Site Not Available

  • University of Maryland Baltimore

    Baltimore, Maryland 21201
    United States

    Site Not Available

  • Mayo Clinic

    Rochester, Minnesota 55902
    United States

    Site Not Available

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire 03756
    United States

    Site Not Available

  • Montefiore Medical Center

    New York, New York 10467
    United States

    Site Not Available

  • Mount Sinai St Luke's

    New York, New York 10025
    United States

    Site Not Available

  • New York Presbyterian Hospital/Columbia University Medical Center

    New York, New York 10032
    United States

    Site Not Available

  • Duke University Medical Center

    Durham, North Carolina 27705
    United States

    Site Not Available

  • WakeMed Health & Hospitals

    Raleigh, North Carolina 27610
    United States

    Site Not Available

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • Baylor Scott & White Research Institute, The Heart Hospital Baylor Plano

    Plano, Texas 75093
    United States

    Site Not Available

  • University of Virginia

    Charlottesville, Virginia 22908
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.